BIO fell 5.68% to $356.25 from $379.55 the previous trading day Weiss Ratings assigns C- (Hold) Market cap is $10.08B Bio-Rad ...

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

Biodesix Inc. (BDSX), a diagnostic solutions company, last week reported strategic progress for two programmes regarding Molecular Residual Disease (MRD) solutions for cancer diagnosis. Biodesix is ...

Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash ...

(Nasdaq: BDSX), a leading diagnostics solutions company, announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease (MRD) solutions ...

Point-of-care molecular diagnostics are gaining traction, reducing costs, improving outcomes and combating antimicrobial resistance, with potential to replace frontline testing protocols.Dublin, Sept.

Biodesix, Inc. a annoncé des avancées stratégiques dans le cadre de deux programmes collaboratifs consacrés aux solutions de suivi de la maladie résiduelle moléculaire guidées par la tumeur ...

Biodesix, Inc. hat strategische Fortschritte bei zwei kooperativen Programmen für tumorinformierte und tumornaive Lösungen ...

LOUISVILLE, Colo. - Biodesix Inc. ( NASDAQ:BDSX) ha annunciato giovedì i progressi compiuti nell’ambito di due programmi ...

Biodesix, Inc. announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical ...

Biodesix, Inc. (NASDAQ:BDSX), une entreprise leader dans le domaine des solutions de diagnostic, a annoncé aujourd'hui des ...

(Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions ...